What You Should Know:–       Inato, the leading platform for clinical trial access and inclusivity, today unveiled new capabilities to help research sites efficiently pre-screen patients for trial opportunities.–       The company’s latest advancement integrates a series of artificial intelligence (AI) models into a unified agent that quickly and securely reviews patient records and assesses eligibility, transforming a historically time-consuming and cumbersome process for sites. Inato: Revolutionizing Clinical Trial Access with AI-Driven SolutionsInato is on a mission to democratize clinical research, ensuring every patient has access to trials regardless of location. By integrating trial planning, site selection, and patient pre-screening into a single AI-powered platform, Inato enhances collaboration among research sites, sponsors, and Contract Research Organizations (CROs). Trusted by leading pharmaceutical companies and utilized by thousands of research sites, Inato streamlines trial operations and improves trial accessibility and representation.Tackling the Patient Enrollment ChallengePatient enrollment remains a significant bottleneck in clinical trials, now taking 25% longer than it did five years ago. Factors such as growing trial complexity, increasing trial sizes, and heightened competition for participants threaten to exacerbate this issue. Leveraging advancements in generative AI, Inato addresses these challenges by:Streamlining patient identification and eligibility reviews.Reducing site burden through efficient AI-driven processes.Accelerating trial timelines while maintaining accuracy and compliance.Transformative AI-Powered Pre-ScreeningInato’s AI-enabled patient pre-screening feature, now available across the United States, significantly optimizes the patient evaluation process without requiring EMR or CTMS integration. Key capabilities include:Assessing patient records against inclusion and exclusion criteria in minutes, with 95% accuracy.Reducing pre-screening times by more than 50%, and up to 90% for early adopters.Empowering site staff to make informed, rapid decisions about patient eligibility.The platform employs an AI agent to de-identify patient records, identify relevant trials, and evaluate eligibility based on complex criteria

In today's episode of Category Visionaries, Frontlines speak with Kourosh Davarpanah, Co-Founder and CEO of Inato, a global clinical trial platform that's raised over $35 Million in funding.

Eli Health, a Montréal, Quebec-based healthtech company working on a saliva-based hormone testing solution, raised C$5M ($3.7M) led by Muse Capital, with participation from RH Capital, Cake Ventures, TELUS Pollinator Fund For Good, Garage Capital, Leva Capital, Real Ventures, Panache, Vectr, and MEDTEQ+.